← back to search

Evripidis Gavathiotis

Weill Cornell Medical College in Qatar · US
Area of research
Molecular Biology · Hematology
Research interest
Research interests include Acute Myeloid Leukemia Research, MicroRNA in disease regulation, Cell death mechanisms and regulation, and Melanoma and MAPK Pathways.
h-index
51
citations
22,124
works
304
NIH funding
primary concept
Biology
email

Recent publications

A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.
2026cited by 3position: contributordoi
RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors.
2026cited by 1position: contributordoi
A molecular glue halts RAS-MAPK signaling.
2026cited by 0position: contributordoi
Chaperone-mediated autophagy protects against retinal photoreceptor degeneration by modulating proteostasis of glucose metabolism enzymes.
2026cited by 0position: contributordoi
Munc13-4-STX7 inhibitors impair endosomal TLR activation and systemic inflammation.
2026cited by 0position: contributordoi
Figure S4 from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors
2026cited by 0position: contributordoi
Figure S3 from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors
2026cited by 0position: contributordoi
Figure S2 from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors
2026cited by 0position: contributordoi
Supplementary Data Legends from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors
2026cited by 0position: contributordoi
Figure S5 from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors
2026cited by 0position: contributordoi
Data from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors
2026cited by 0position: contributordoi
Figure S1 from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors
2026cited by 0position: contributordoi
LRP8 is a receptor for tick-borne encephalitis virus
Nature 2025cited by 23position: middledoi
Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer.
2025cited by 15position: contributordoi
Small molecule OPA1 inhibitors amplify cytochrome c release and reverse cancer cells resistance to Bcl-2 inhibitors
Science Advances 2025cited by 12position: middledoi
Small molecule OPA1 inhibitors amplify cytochrome c release and reverse cancer cells resistance to Bcl-2 inhibitors.
2025cited by 11position: contributordoi
LRP8 is a receptor for tick-borne encephalitis virus.
2025cited by 10position: contributordoi
Mechanism of dimer selectivity and binding cooperativity of BRAF inhibitors
eLife 2025cited by 5position: contributordoi
Small molecule disruption of RARα/NCoR1 interaction inhibits chaperone-mediated autophagy in cancer.
2025cited by 4position: contributordoi
Identification of functional rare coding variants in IGF-1 gene in humans with exceptional longevity.
2025cited by 2position: contributordoi
Mechanism of dimer selectivity and binding cooperativity of BRAF inhibitors.
2025cited by 2position: contributordoi
Quiescent OXPHOS-High Triple-Negative Breast Cancer Cells That Persist After Chemotherapy Depend on BCL-XL for Survival.
2025cited by 1position: contributordoi
Data from Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
2025cited by 1position: contributordoi
Defective chaperone-mediated autophagy in the retinal pigment epithelium of age-related macular degeneration patients.
2025cited by 0position: contributordoi
Supplementary Methods from Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
2025cited by 0position: contributordoi
Mechanism of Dimer Selectivity and Binding Cooperativity of BRAF Inhibitors
2025cited by 0position: contributordoi
Supplementary Table S1 from Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
2025cited by 0position: contributordoi
Supplementary Table S5 from Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
2025cited by 0position: contributordoi
Supplementary Table S2 from Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
2025cited by 0position: contributordoi
Supplementary Table S4 from Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
2025cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 168 papers (2019–2026)Aristotelis Tsirigos · NYU Langone’s Laura and Isaac Perlmutter Cancer Center70 papers (2019–2025)C. Glytsou · NYU Langone Health69 papers (2019–2025)Iannis Aifantis · NYU Langone Health56 papers (2019–2025)Michael Andreeff · The University of Texas MD Anderson Cancer Center55 papers (2023–2025)Raoul Tibes · AstraZeneca (United Kingdom)55 papers (2019–2025) · 54 papers (2023–2025) · 54 papers (2023–2025)Xufeng Chen · NYU Langone’s Laura and Isaac Perlmutter Cancer Center54 papers (2023–2025)Jo Ishizawa · The University of Texas MD Anderson Cancer Center54 papers (2023–2025)M. Anna Zal · Scripps MD Anderson Cancer Center54 papers (2023–2025) · 54 papers (2023–2025)Soobeom Lee · NYU Langone’s Laura and Isaac Perlmutter Cancer Center54 papers (2023–2025)Tomasz Zal · The University of Texas MD Anderson Cancer Center54 papers (2023–2025)Zhengxi Sun · New York University54 papers (2023–2025)Bing Z. Carter · The University of Texas Health Science Center at Houston54 papers (2023–2025)Dimitrios Papaioannou · Mitera Hospital54 papers (2023–2025) · 54 papers (2023–2025)Bettina Nadorp · City University of Seattle54 papers (2023–2025) · 54 papers (2023–2025)